Aktie A0M1WB NEUROBIOLOGICAL TECHNOLOGIES, INC.
Zu einer Liste hinzufügen
Um diese Funktionalität nutzen zu können, müssen Sie Mitglied sein
EinloggenRegistrieren

Andere Sprachen Neurobiological Technologies, Inc.

Aktien

A0M1WB

US64124W3043

NTII

Markt geschlossen - OTC Markets
Andere Börsenplätze
 20:29:56 17.04.2024 		% 5 Tage % 1. Jan.
0,000001 USD -.--% Intraday Chart für Neurobiological Technologies, Inc. -.--% -.--%

Andere Sprachen

Suchen
Ergebnisse ansehen
Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!
100% kostenlose Registrierung
Neurobiological Technologies Inc. Announces Extraordinary Dividend, Payable on December 27, 2012
NEUROBIO TECH : Neurobiological Technologies Announces Extraordinary Dividend of $0.18 per Share
NEUROBIO TECH : Neurobiological Technologies Announces Stockholder Approval of Plan of Liquidation and Dissolution
NEUROBIO TECH : Neurobiological Technologies Announces Intent to File Form 25 to Delist Common Stock From the NASDAQ Capital Market
NEUROBIO TECH : Neurobiological Technologies Receives Nasdaq Closing Bid Price Notification
NEUROBIO TECH : Neurobiological Technologies Announces Termination of its License and Cooperation Agreement with Merz and Children's Medical Center
NEUROBIOLO TCHNLGS : Neurobiological Technologies Reports Third Quarter Fiscal 2009 Financial Results
NEUROBIOLO TCHNLGS : Neurobiological Technologies Reports Receipt of $1.5 Million Royalty Payment for Quarterly Sales of Memantine
NEUROBIOLO TCHNLGS : Neurobiological Technologies Announces Hiring of Advisor to Seek Sale of Company
NEUROBIOLO TCHNLGS : Neurobiological Technologies Reports Second Quarter Fiscal 2009 Financial Results
NEUROBIOLO TCHNLGS : Neurobiological Technologies Reports Receipt of $1.5 Million Royalty Payment for Quarterly Sales of Memantine
NEUROBIOLO TCHNLGS : Neurobiological Technologies Announces Suspension of Viprinex Development
NEUROBIOLO TCHNLGS : Neurobiological Technologies Announces Viprinex(TM) Does Not Pass Interim Futility Analysis
NEUROBIOLO TCHNLGS : Neurobiological Technologies, Inc. Reports First Quarter Fiscal Year 2009 Financial Results
NEUROBIOLO TCHNLGS : Neurobiological Technologies to Present at the Rodman & Renshaw 10th Annual Healthcare Conference in New York on November 10
NEUROBIOLO TCHNLGS : Neurobiological Technologies Sets Date for First Quarter Financial Results
NEUROBIOLO TCHNLGS : Neurobiological Technologies Reports Receipt of $2 Million Royalty Payment for Quarterly Sales of Memantine
NEUROBIOLO TCHNLGS : Neurobiological Technologies to Present at the BIO Investor Forum in San Francisco on October 30, 2008
NEUROBIOLO TCHNLGS : Neurobiological Technologies Announces FDA Agreement to Consolidate Viprinex Phase 3 Trials Accelerating Time to Pivotal Data
NEUROBIOLO TCHNLGS : Neurobiological Technologies Announces Update Call on Viprinex (TM) Phase 3 Trial Program
Keine Ergebnisse zu dieser Suche
Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Filter

Suchen

Datum der Veröffentlichung

Vom

Bis

  1. Börse
  2. Aktien
  3. A0M1WB Aktie
  4. Nachrichten Neurobiological Technologies, Inc.
  5. Andere Sprachen